PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Thousand Oaks Surgeon Offers Non-Surgical Facelift With JUVEDERM VOLUMA XC

Dr. Kouros Azar provides injections of the dermal filler JUVEDERM VOLUMA XC to patients at his Thousand Oaks plastic surgery practice, where he was one of the first plastic surgeons in the U.S. to use the breakthrough cheek volumizer.

Thousand Oaks Surgeon Offers Non-Surgical Facelift With JUVEDERM VOLUMA XC
2014-03-30
THOUSAND OAKS, CA, March 30, 2014 (Press-News.org) Renowned plastic surgeon Dr. Kouros Azar (www.azarplasticsurgery.com) is the leading injector of JUVEDERM VOLUMA XC in Thousand Oaks, where his plastic surgery practice offers the new dermal filler as an anti-aging option that doesn't require surgery.

Dr. Azar was one of only 2 plastic surgeons in Southern California to receive VOLUMA XC before anyone else after it was approved by the FDA in fall 2013, and he is now one of a handful of surgeons in the region who trains other doctors in the use of the product. More patients get VOLUMA XC injections at the plastic surgeon's Thousand Oaks practice than anywhere else in the area.

"I'm proud to be one of the first surgeons in the country to offer this breakthrough product and to be the top VOLUMA injector in the region," Dr. Azar says.

VOLUMA XC is an injectable gel and the only filler approved by the FDA to restore volume to the mid-face area, including the cheeks. Plastic surgeons consider it a milestone product because it lasts a long time and effectively mimics some of the results of a facelift. In Thousand Oaks, Dr. Azar says, many of his patients desire a more youthful appearance but aren't ready for plastic surgery.

"Plastic surgeons have known for a long time that the key to an effective facelift is not simply stretching the skin tighter, but also lifting and rearranging the fat in the mid-face," Dr. Azar says. "VOLUMA XC restores volume in the cheeks that is lost as people age. It can delay, or even eliminate, the need for a facelift in some patients, and it's more affordable than surgery."

The key ingredient of VOLUMA XC, like many other popular facial fillers, is hyaluronic acid, a substance that is found naturally in the body. That means allergic reactions are extremely rare and the cosmetic results look very natural.

"One of the most attractive features of VOLUMA XC is that it's been clinically tested to last up to 2 years," Dr. Azar says. "Most other fillers don't last that long."

Dr. Azar adds that many patients get a complete facial rejuvenation when combining VOLUMA XC with other injectables, such as BOTOX Cosmetic and other dermal fillers at his Ventura County office.

"The results are truly remarkable," he says. "You can target different areas with these different products and make your face look years younger, and you don't have the downtime or expense of surgery. VOLUMA XC is a big step forward for these non-surgical treatments."

Dr. Kouros Azar (www.azarplasticsurgery.com) is a board-certified plastic surgeon serving Thousand Oaks, Simi Valley, Agoura Hills, and Westlake Village. After earning his medical degree from Case Western Reserve University, Dr. Azar completed a general surgery residency at University of Arizona and a fellowship in plastic and reconstructive surgery at the University of Utah. He is a member of The American Society for Aesthetic Plastic Surgery and the American Society of Plastic Surgeons. He performs a variety of reconstructive and cosmetic surgical techniques for the face, breasts, and body, and he offers a wide range of non-surgical aesthetic treatments.

[Attachments] See images for this press release:
Thousand Oaks Surgeon Offers Non-Surgical Facelift With JUVEDERM VOLUMA XC

ELSE PRESS RELEASES FROM THIS DATE:

Risk Management Executive, James Hice, Named Risk Manager and General Counsel at McCusker & Company

Risk Management Executive, James Hice, Named Risk Manager and General Counsel at McCusker & Company
2014-03-30
Risk Management executive, and highly-regarded industry insider, James Hice, was today named Risk Manager and General Counsel at McCusker & Company, a leading international provider of warranty protection solutions for the commercial and consumer electronics industry. "I am pleased to name James Hice our new Risk Manager and General Counsel," said McCusker & Company Chief Executive Officer Will L. McCusker. "His connections, insight, expertise and industry knowledge will be invaluable for our company." Hice was the Vice President of Operations and Procurement ...

Envision Built Offers Custom Built Transformations of Screened Porches and Patios into Spacious Three Season Sunrooms to Extend Living Spaces in Cary, Durham and the Greater Raleigh NC Area

2014-03-30
Envision Built Home Remodeling is a custom home renovation specialist - transform your screened porch or patio into a three seasons sunroom, extending the living space of your home. Envision Built is an award-winning remodeling designer and builder. "A fairly easy way to extend the living space in your home is convert your screened porch or patio into a beautiful sunroom," said Bill Ahle, Owner of Envision Built. "Every major renovation begins with a five hour design session working with our interior designer to help you develop a plan, select color schemes and to map ...

SchureMed to Unveil Schure Loc XPS Medical Device at AORN in Chicago

SchureMed to Unveil Schure Loc XPS Medical Device at AORN in Chicago
2014-03-30
SchureMed announced today plans to present their newest and most innovative surgical positioning device at the AORN Show at McCormick Place in Chicago IL. The Schure Loc XPS Extremity Positioning System advances surgical patient positioning by combining both absolute rigid fixation of the patient's limb with unlimited range of motion both pre- and intra-operatively during shoulder arthroscopy, rotator cuff and total shoulder replacement procedures. Unlike other devices that use bulky hydraulic systems and supplementary power units, the Schure Loc XPS employs an ingenious ...

Texas Based Modern Intellects Artist Gift Releases The Trip EP

Texas Based Modern Intellects Artist Gift Releases The Trip EP
2014-03-29
The release of Gift's EP "The Trip" has been eagerly awaited by fans since mid-2013, the uniquely creative video countdown gave fans but a glimpse inside the mind of the independent rapper and the creative process of the project, leaving listeners and viewers wanting more. Gift first began writing at 16 years old after a serious hamstring injury that ended his future in track and field, but ended up being what would pave the way for his future. Fans have the choice of downloading the EP for free or making a donation by visiting www.giftrapsmusic.com or the artist's SoundCloud ...

Relaxed blood pressure guidelines cut millions from needing medication

2014-03-29
DURHAM, N.C. – New guidelines that ease the recommended blood pressure could result in 5.8 million U.S. adults no longer needing hypertension medication, according to an analysis by Duke Medicine researchers. The findings are the first peer-reviewed analysis to quantify the impact of guidelines announced in February by the Eighth Joint National Committee. In a divisive move, the committee relaxed the blood pressure goal in adults 60 years and older to 150/90, instead of the previous goal of 140/90. Blood pressure goals were also eased for adults with diabetes and kidney ...

Study estimates proportion of adults affected by new blood pressure guideline

2014-03-29
Applying the updated 2014 blood pressure (BP) guideline to the U.S. population suggests that nearly 6 million adults are no longer classified as needing hypertension medication, and that an estimated 13.5 million adults would now be considered as having achieved goal blood pressure, primarily older adults, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions. Ann Marie Navar-Boggan, M.D., Ph.D., of Duke University Medical Center, Durham, N.C., and colleagues quantified the proportion of adults potentially ...

US, European cholesterol guidelines differ in statin use recommendations

2014-03-29
Application of U.S. and European cholesterol guidelines to a European population found that proportions of individuals eligible for statins differed substantially, with one U.S. guideline recommending statins for nearly all men and two-thirds of women, proportions exceeding those of the other guidelines, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions. The common approach in cardiovascular disease (CVD) primary prevention is to identify individuals at high enough risk to justify more intensive lifestyle ...

Analysis supports use of risk equations to guide statin therapy

2014-03-29
In an analysis of almost 11,000 patients, an assessment of equations that help guide whether a patient should begin taking a statin (cholesterol lowering medication) found that observed and predicted 5-year atherosclerotic cardiovascular disease risks were similar, suggesting that these equations are helpful for clinical decision making, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. The American College of Cardiology (ACC) and the American Heart Association (AHA) recently published ...

Celiac disease linked to increased risk of coronary artery disease

2014-03-29
People with celiac disease may have a near two-fold increased risk of coronary artery disease compared with the general population, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session. The study is the first to look at the association between celiac disease and coronary artery disease and adds to the evolving understanding of how systemic inflammation and autoimmune processes might influence cardiovascular disease development. Data also showed a slightly higher risk of stroke among people with celiac disease compared ...

Are statins good for your love life?

2014-03-29
Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session. Erectile dysfunction is common in older men, especially among those with cardiovascular risk factors where cholesterol-lowering statins are frequently prescribed. Previous research has suggested a negative association between statin therapy and testosterone levels, leading to ...

LAST 30 PRESS RELEASES:

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Study prompts new theory of human-machine communication

New method calculates rate of gene expression to understand cell fate

Researchers quantify rate of essential evolutionary process in the ocean

Innovation Crossroads companies join forces, awarded U.S. Air Force contract

Using new blood biomarkers, USC researchers find Alzheimer’s disease trial eligibility differs among various populations

Pioneering advances in in vivo CAR T cell production

Natural medicines target tumor vascular microenvironment to inhibit cancer growth

Coral-inspired pill offers a new window into the hidden world of the gut

nTIDE September2025 Jobs Report: Employment for people with disabilities surpasses prior high

When getting a job makes you go hungry

Good vibrations could revolutionize assisted reproductive technology

[Press-News.org] Thousand Oaks Surgeon Offers Non-Surgical Facelift With JUVEDERM VOLUMA XC
Dr. Kouros Azar provides injections of the dermal filler JUVEDERM VOLUMA XC to patients at his Thousand Oaks plastic surgery practice, where he was one of the first plastic surgeons in the U.S. to use the breakthrough cheek volumizer.